|
Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies. |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Leo Pharma; MSD; Novartis; Pfizer |
Travel, Accommodations, Expenses - Ipsen; Pfizer; Roche |
|
|
Consulting or Advisory Role - Eisai; Ipsen; Merck Serono; Roche |
Travel, Accommodations, Expenses - Pfizer |
|
|
Consulting or Advisory Role - Bayer |
Travel, Accommodations, Expenses - Sanofi |
|
|
Honoraria - Bayer; Pfizer |
Consulting or Advisory Role - Bayer; Pfizer |
|
|
No Relationships to Disclose |
|
|
Research Funding - AB Science (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Travel, Accommodations, Expenses - PharmaMar |
|
|
Honoraria - Roche; Synthon |
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; Macrogenics; Novartis; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pfizer; Roche Belgium |
|
|
No Relationships to Disclose |
|
|
Employment - Cantargia AB |
Stock and Other Ownership Interests - Cantargia AB |
Travel, Accommodations, Expenses - Cantargia AB |
|
|
No Relationships to Disclose |